Humacyte, INC DEF 14A proxy statements

Humacyte, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 9, 2026, to elect directors, approve executive compensation, ratify auditor selection, and vote on a significant increase in authorized shares.

Humacyte, Inc. has filed a definitive proxy statement with the SEC, indicating upcoming shareholder actions.

Humacyte is asking stockholders to approve an amendment to its corporate charter to increase the number of authorized common shares from 250 million to 350 million at the upcoming annual meeting.

Humacyte, Inc. has filed a definitive proxy statement with the SEC.

Humacyte, Inc. announces its annual meeting of stockholders to be held virtually on June 11, 2024, with key proposals including the election of directors and ratification of the company's independent accounting firm.